­
­
­
­

Inventi Impact - Biosimilars

Patent Watch

  • Method for simultaneous production of multiple proteins; vectors and cells for use therein

    Described is the production of proteins in a host cell. Even more specifically, described are methods for improving expression of two or more proteins in a cells or host cell. The methods are suited for production of, for example, recombinant antibodies that can be used in pharmaceutical preparations or as diagnostic tools. In certain embodiments, provided are methods for obtaining a cell that expresses two or more proteins comprising providing the cell with two or more protein expression units encoding two or more proteins, characterized in that at least two of the protein expression units comprise at least one STAR sequence.

  • Stabilized polypeptide compositions

    The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.

  • Regulated aptamer therapeutics

    Materials and methods of use thereof are presented for the treatment of diabetes and other diseases. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of diabetes disease are presented with methods of administering these therapeutic compositions.

  • Method and apparatus for intervertebral disc support and repair

    An intervertebral disc device is provided to support or repair one or both of the disc annulus and the disc nucleus. The intervertebral disc device includes an annulus support and an elongated member to support the disc nucleus. The disc annulus support has an elongated wire and an annulus closure. The disc nucleus has an elongated member that is expandable. Any of the devices can be loaded with biologics. Moreover, any of the devices may include a scarring factor to promote fibrous growth.

  • Methods for protecting and regenerating bone marrow using CXCR3 agonists and antagonists

    CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment of cancer and bone marrow diseases.

  • System and method for automatically switching prescriptions in a retail pharmacy to a new generic drug manufacturer

    An automatic manufacturer switchover function to switch a set of future new, transfer, refill, and/or copy prescriptions to a new manufacturer product for a pharmacy. Furthermore, the claimed method and system may allow for a tiered approach to a manufacturer switch by allowing a corporate entity or owner of a pharmacy network to designate a pharmacy wide preferred manufacturer (or generic product) while giving a local pharmacy the power to decide when to implement a switchover at a local level. In one embodiment, the claimed switching system and process may also provide indications to pharmacists and customers to guide a transition from one manufacturer to another, thereby preserving customer perception of quality and pharmacy reputation.

  • METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF

    Provided herein are Heteroaryl Compounds having the following structure: ##STR00001## wherein R.sup.1, R.sup.3, R.sup.4, L, X, Y, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  • TASTE MASKED TOPIRAMATE COMPOSITION AND AN ORALLY DISINTEGRATING TABLET COMPRISING THE SAME

    In various embodiments, the present invention is directed to a taste masked pharmaceutical composition comprising a therapeutically effective amount of taste masked sulfamate-substituted monosaccharide particles comprising a sulfamate-substituted monosaccharide or a pharmaceutically acceptable salt or derivative thereof that are coated with one or more taste-masking layers, and optionally one or more of taste-masked neltrexone, 5-HT.sub.3 receptor antagonist, phentermine, and vitamin B-12. The present invention relates to methods of making the taste masked and ODT compositions, and methods of using the compositions for treating a patient subject to an epileptic condition, migraines, dysphagia, achieving/maintaining weight loss, or alcoholism or drug addiction.

  • A SEMICONDUCTOR FOR MEASURING BIOLOGICAL INTERACTIONS

    An apparatus and method are disclosed for electrically directly detecting biomolecular binding in a semiconductor. The semiconductor can be based on electrical percolation of nanomaterial formed in the gate region. In one embodiment of an apparatus, a semiconductor includes first and second electrodes with a gate region there between. The gate region includes a multilayered matrix of electrically conductive material with capture molecules for binding target molecules, such as antibody, receptors, DNA, RNA, peptides and aptamer. The molecular interactions between the capture molecules and the target molecules disrupts the matrix's continuity resulting in a change in electrical resistance, capacitance or impedance. The increase in resistance, capacitance or impedance can be directly measured electronically, without the need for optical sensors or labels. The multi-layered matrix can be formed from a plurality of single-walled nanotubes, graphene, or buckeyballs or any kind of conductive nanowire, such as metal nanowires or nanowires made from conductive polymers.

  • PROTEIN SCREENING METHODS

    The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro.

  • IMMUNOSTIMULATORY OLIGORIBONUCLEOTIDES

    The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).

  • FUNCTIONALIZED POLYPEPTIDES

    The invention provides functionalized polypeptides, especially therapeutic polypeptides (e.g., scFv), comprising a linker sequence that can be rapidly and specifically functionalized by the addition of one or functional moieties (e.g., PEG) or binding specificities (e.g., an amino acid sequence with a particular binding specificity). Such functionalized polypeptides are advantageous in that they have improved pharmacokinetic properties (e.g., improved in vivo half-life, tissue penetration and tissue residency time) over non-functionalized polypeptides. Methods for the rapid and reproducible generation of functionalized polypeptides are also provided.

  • ANTISENSE MODULATION OF INTERLEUKINS 17 AND 23 SIGNALING

    Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity.

  • OXYGEN SENSOR

    The present invention generally relates to systems and methods for determining oxygen in a sample, or in a subject. In one aspect, the present invention is generally directed to an article exhibiting a determinable feature responsive to oxygen, such as oxygen-sensitive particles. The particles may exhibit a determinable change with a change in oxygen concentration, and such particles can accordingly be used to determine oxygen. For example, in one set of embodiments, the particles may be at least partially coated with a protein, such as hemoglobin, that is able to interact with oxygen. In some cases, the protein may aggregate under certain conditions (e.g., under relatively low oxygen concentrations), and such protein aggregation may be used, for example, to cause the particles to become aggregated, which can be determined in some way. In some cases, such aggregation may be irreversible; i.e., the degree of aggregation corresponds to the most extreme oxygen concentrations that the proteins were exposed to. Such articles may be used, for example, to determine oxygen within a sample, or within a subject, such as a human subject. For instance, the article may be formed as a skin patch, or administered to the skin of a subject, e.g., on the surface of the skin, within the dermis or epidermis, etc., to determine oxygen within the subject.

  • GENERATION AND CHARACTERIZATION OF ANTI-NOTCH ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC USE

    The present invention relates to mammalian antibodies, preferably fully human monoclonal antibodies and antigen-binding portions thereof that specifically bind to a cell surface receptor, wherein the receptor protein is a Notch1 receptor protein. Some of the disclosed antibodies bind Notch1 to the exclusion of other members of the Notch receptor family, while other antibodies bind Notch 1 and Notch3. Nucleic acid molecules encoding the Notch antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of Notch1 or Notch3 including aberrant activation of each of these receptors.

  • IL-8 BIOMARKER FOR MONITORING CANCER TREATMENT

    The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.

  • Buoy Suspension Fractionation System

    A separator that uses centrifugation to fractionate a suspension such as blood comprises a separation container and a buoy. The buoy is carried in the separation container and has a tuned density that is configured to reach an equilibrium position in a suspension. The guide surface is carried on the buoy upper surface and is inclined to an accumulation position near a buoy perimeter. The buoy suspension fractionation system can be used in a method of isolating a fraction from a suspension, and in a method for re-suspending particulates for withdrawal.

  • Gaseous Sterilization of Impermeable Containers Through Use of Porous Material

    A gas-impervious container having a gas-permeable porous insert, wherein the insert contacts a flowable biomedical material, for improving access of the sterilant gas to the material.

  • Reinforced Absorbable Multi-Layered Fabric for Hemostatic Applications

    The present invention is directed to a synthetic fabric comprising a multi-layered nonwoven fabric made from staples of a polyglycolide/polylactide copolymer, each layer having a different density. The multi-layer fabric can be used as a reinforced absorbable hemostat medical device.

  • Method of Detecting Filter Extractables in Biopharmaceutical Products By Liquid Chromatography-Mass Spectrometry.

    The invention uses liquid chromatography-mass spectrometry to verify the presence or absence of the extractables introduced into a biopharmaceutical product during manufacture, filtration or storage at above a certain concentration. The method disclosed herein can be used to detect the presence of extractables in the actual biopharmaceutical product rather than a surrogate solvent system. Detection of the extractables in the actual drug product provides an accurate description of the leachables profile likely to be introduced to the human or animal patient. In one embodiment, the extractable are introduced by filtration of the bio-pharmaceutical product.

  • METHODS AND COMPOSITIONS FOR REPAIR OF CARTILAGE USING AN IN VIVO BIOREACTOR

    Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.

  • SYSTEMS AND METHODS FOR FREEZING, STORING AND THAWING BIOPHARMACEUTICAL MATERIALS

    A system for using freezing, storing and thawing biopharmaceutical materials which includes a holder and a container for holding biopharmaceutical materials therein. The holder has a cavity and the container is received in the cavity. The holder includes a first portion and second portion. The container is received between the first portion and the second portion to connect the container to the holder. The holder includes an interior cradle having a bottom and edges extending from the bottom. The cradle bounds the cavity. An outer rim is connected to the cradle and separated from the cavity. The bottom includes an inner surface facing the cavity receiving the container and an outer surface. The outer surface of the bottom is recessed relative to an outer surface of the outer rim.

  • Stable Suspension Formulation

    A physicochemically stable aqueous composition including clozapine suspension.

  • System and Method for Sorting Data

    A method and apparatus that enables a user to sort data from one or more sample lots, which may be obtained via a network, such as the Internet, into a composite parameter structure. The composite parameter structure is a function of one or more parameters corresponding to one or more characteristics associated with one or more sample lots. The composite parameter structure representation may be printed, stored, or transmitted to another location. A server device that is coupled and working in conjunction with a client device may implement the present invention.

  • NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF

    Described herein are automatic injectors suitable for administration of a non-sedating antihistamine, and methods of using the automatic injectors. A specific non-sedating antihistamine is cetirizine. The automatic injectors are useful in treating acute urticaria or angioedema associated with an acute allergic reaction including anaphylaxis.

  • ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION

    The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject.

  • Fast-acting insulin formulation

    A complex between an insulin and a polysaccharide comprising carboxyl functional groups is described, the polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, the phenylalanine derivative being chosen from phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide and ethylbenzylamine or from phenylalanine esters, and the insulin being either a human insulin or an insulin analog. A pharmaceutical composition including at least one complex, especially in the form of an injectable solution, is also described.

  • Human Growth Hormone Formulations

    Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins.

  • NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS

    The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

  • Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues

    The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H.sub.2 receptor antagonist, a serotonin 5-HT.sub.4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.

  • USE OF A GHRELIN AGONIST TO IMPROVE THE CATABOLIC EFFECTS OF GLUCOCORTICOID TREATMENT

    A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib.sup.2, Glu.sup.3(NH-hexyl)]hGhrelin(1-28)-NH.sub.2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.

  • METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS

    The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.

  • LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME

    Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.

  • MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY

    Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.

  • IMMUNOLOGICAL COMPOSITIONS AS CANCER THERAPEUTICS

    The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.

  • BICYCLO-HEPTAN-2-AMINES

    The present invention provides bicyclo-heptan-2-amines that selectively bind to the sigma-2 receptor and are useful in the treatment of diseases related to the sigma-2 receptor, for example, cancer and neurological disorders.

  • METHODS OF IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS

    A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing WIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the Fc.gamma.RIIB receptor and in turn inhibiting a cellular-mediated inflammatory response.

  • SIMULTANEOUS, INTEGRATED SELECTION AND EVOLUTION OF ANTIBODY/PROTEIN PERFORMANCE AND EXPRESSION IN PRODUCTION HOSTS

    The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!.TM.) allows for simultaneous evolution of protein performance and expression optimization.

  • BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF INSULIN RESISTANCE

    The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject.

  • PARY-XYLENE BASED MICROFILM ELUTION DEVICES

    This invention is in the field of controlled elution devices for therapeutic delivery. There exists a need for a stand-alone capable device for the localized and extended delivery of a therapeutic. This need is overcome by the present invention having an exemplary embodiment comprised of a microfilm base (12), a reservoir of a therapeutic (14) disposed about the microfilm base (12) and a top layer (24) that is (i) a plurality of laminated layers (24) of para-xylyelne polymer and/or (ii) para-xylyelne polymer endowed with oxidatively functionalized para-xyele units. The thicknesses of the device is optimally in the range of about 10 to about 200 microns. The device is usable for the localized release of broad spectrum therapeutics for interventional and preventative medicine.

  • HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS

    The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.

  • NANO-VEHICLE DERIVED FROM TUMOR TISSUE, AND CANCER VACCINE USING SAME

    The present invention relates to a cancer vaccine, and specifically, to a pharmaceutical composition for treating cancer containing a nano-vehicle derived from tumor tissue, and a method for treating cancer using the nano-vehicle derived from tumor tissue, and the like. According to the present invention, a nano-vehicle antigen derived from tumor tissue indicates a high yield while having properties similar to those of an exocellular vehicle, and can be variously modified, and is thus expected to be very useful for developing the cancer vaccine.

  • LAWSONIA VACCINE AND METHODS OF USE THEREOF

    The present invention provides improved vaccination methods for increased protection against ileitis. The methods provide for the vaccination of young animals, preferably piglets, between 10 and 26 days of age, vaccination of pregnant sows during the second or third stages of gestation, and a combination of these methods. Vaccination of the pregnant sows can occur using repeated and/or high doses of Lawsonai antigen prior to farrowing.

  • HUMAN CYTOMEGALOVIRUS VACCINE

    Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (CMV) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the UL130 and UL131 components of the gH/gL/UL128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of UL130 and amino acid residues 90-106 of UL131. The combination peptides, polypeptides and proteins, and the nucleic acids encoding them, may be used in vaccines, and as diagnostic and research tools.

  • BROADLY PROTECTIVE SHIGELLA VACCINE BASED ON TYPE III SECRETION APPARATUS PROTEINS

    Broad-based, cross-protective, O-serotype independent vaccines against Shigella and related pathogenic organisms are provided. The vaccines comprise one or more of the type III secretion (TTS) apparatus needle proteins IpaD and IpaB, and/or the IpaB cognate chaperone protein IpgC. Chimeric proteins of IpaD and IpaB, and/or IpgC are also encompassed.

  • PLANT-DERIVED CHOLERA AND MALARIA VACCINE

    Described herein are methods for simultaneously immunizing a subject against Cholera and Malarial infection. Specifically exemplified herein are methods that involve administering compositions comprising a CTB-AMA1 or CTB-MSP1 derived from plants having plastids transformed to express such conjugates.

  • DEVICE, METHOD, AND SYSTEM FOR NEURAL MODULATION AS VACCINE ADJUVANT IN A VERTEBRATE SUBJECT

    A method for enhancing an immune response in a vertebrate subject is described. The method includes providing at least one energy stimulus configured to modulate one or more nervous system components of the vertebrate subject, and administering one or more immunogen to the vertebrate subject, wherein the at least one energy stimulus and the one or more immunogen are provided in a combination and in a temporal sequence sufficient to enhance an immune response in the vertebrate subject.

  • COMPOSITIONS, METHODS AND USES FOR POXVIRUS ELEMENTS IN VACCINE CONSTRUCTS

    Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.